Table 2 Comparison of the evaluation and validation sample characteristics.
| Â | Characteristic | Evaluation sample | Validation sample | Difference between evaluation and validating sample |
|---|---|---|---|---|
| Â | number of subjects | 317 | 318 | Â |
|  | mean age (SD, min.—max.)(yrs) | 46.8 (11.3) | 46.4 (10.6) | t-test p = 0.606 |
| Â | number female (%) | 234 (73.8) | 217 (68.2) | chi-square p = 0.144 |
|  | mean disease duration (SD, min.—max.)(yrs) | 16.0 (9.7, 2—49) | 14.2 (9.4, 2—45) | t-test p = 0.064 |
disease type, n (%) | pp | 25 (7.9) | 29 (9.1) | chi-square p = 0.932 |
| Â | rr | 169 (53.3) | 168 (52.8) | Â |
| Â | sp | 88 (27.8) | 89 (28.0) | Â |
| Â | unknown | 35 (11.0) | 32 (10.1) | Â |
EDSS, n (%) | 0—4.0 | 104 (32.8) | 110 (34.6) | chi-square p = 0.88 |
|  | 4.5—6.5 | 101 (31.9) | 95 (29.9) |  |
|  | 7.0—7.5 | 70 (22.1) | 66 (20.8) |  |
|  | 8.0—9.5 | 38 (12.0) | 42 (13.2) |  |
| Â | unknown | 4 (1.3) | 5 (1.6) | Â |
|  | mean 100 mm VAS fatigue score (SD, min.—max.) | 55.73 (24.4, 0—100) | 52.11 (23.19, 0—100) | t-test p = 0.059 |